Literature DB >> 36201125

Risk of bleeding-related complications after kidney biopsy in patients with systemic lupus erythematosus.

Eun Song Kang1, Soo Min Ahn1, Ji Seon Oh2, Hyosang Kim3, Won Seok Yang3, Yong-Gil Kim1, Chang-Keun Lee1, Bin Yoo1, Seokchan Hong4.   

Abstract

OBJECTIVE: Kidney biopsy is essential for the diagnosis and classification of lupus nephritis. Percutaneous biopsy has a risk of bleeding-related complications; however, data on the risk of percutaneous kidney biopsy in patients with systemic lupus erythematosus (SLE) are scarce. In this study, we aimed to investigate the rate of bleeding-related complications and to examine the risk factors for complications of kidney biopsy in patients with systemic lupus erythematosus (SLE). 
METHODS: We retrospectively reviewed the medical records of patients with SLE who underwent ultrasound-guided percutaneous kidney biopsy between 2002 and 2020 at a tertiary referral center. Minor complications were defined as hematoma and passing hematuria not requiring an intervention. Major complications included bleeding events that required interventions after the biopsy. Statistical analysis with a multivariate logistic regression model was performed.
RESULTS: In a total of 277 patients with SLE, the rate of overall bleeding-related complications after kidney biopsy was 19.9% (minor 13.0%; major 6.9%). Among patients with major complications, 84.2% needed blood transfusion alone without embolization or surgery, whereas the remaining three patients needed embolization for bleeding control. Multivariate analysis revealed that thrombocytopenia (odds ratio [OR] 7.186, 95% confidence interval [CI] 2.315-22.300), and low eGFR (OR 3.478, 95% CI 1.094-11.056) were significantly associated with the risk of major bleeding-related complications after kidney biopsy.
CONCLUSION: Percutaneous kidney biopsy is accompanied by the risk of bleeding-related complications; however, most events in our study did not require vascular intervention for bleeding control. Low platelet count and low estimated glomerular filtration rate (eGFR) significantly increase the risk of complications after kidney biopsy in patients with SLE. Key Points • The rate of overall bleeding-related complications after kidney biopsy was about 20% of patients with SLE. • The most commonly observed events were gross hematuria followed by blood transfusion. • Thrombocytopenia and poor kidney function areis an important risk of bleeding-related complications after kidney biopsy.
© 2022. The Author(s), under exclusive licence to International League of Associations for Rheumatology (ILAR).

Entities:  

Keywords:  Complication; Kidney biopsy; Lupus nephritis; Risk factor; Systemic lupus erythematosus

Year:  2022        PMID: 36201125     DOI: 10.1007/s10067-022-06394-7

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   3.650


  19 in total

1.  Complications of the percutaneous kidney biopsy.

Authors:  William L Whittier
Journal:  Adv Chronic Kidney Dis       Date:  2012-05       Impact factor: 3.620

2.  Prognostic factors in lupus nephritis: diagnostic and therapeutic delay increases the risk of terminal renal failure.

Authors:  Mikkel Faurschou; Henrik Starklint; Poul Halberg; Søren Jacobsen
Journal:  J Rheumatol       Date:  2006-08       Impact factor: 4.666

3.  Risk Factors Associated with Major Complications after Ultrasound-Guided Percutaneous Renal Biopsy of Native Kidneys.

Authors:  Beatriz Pombas; Eva Rodríguez; Juan Sánchez; Aleksandar Radosevic; Javier Gimeno; Marcos Busto; Clara Barrios; Laia Sans; Julio Pascual; María José Soler
Journal:  Kidney Blood Press Res       Date:  2019-12-10       Impact factor: 2.687

Review 4.  Lupus nephritis: is the kidney biopsy currently necessary in the management of lupus nephritis?

Authors:  Giovanna Giannico; Agnes B Fogo
Journal:  Clin J Am Soc Nephrol       Date:  2012-09-13       Impact factor: 8.237

5.  Renal outcomes of transient proteinuria in patients with systemic lupus erythematosus treated with corticosteroid therapy alone.

Authors:  Young-Eun Kim; Soo Min Ahn; Ji Seon Oh; Yong-Gil Kim; Chang-Keun Lee; Bin Yoo; Seokchan Hong
Journal:  Lupus       Date:  2022-04-03       Impact factor: 2.911

6.  Predictors of bleeding complications in percutaneous ultrasound-guided renal biopsy.

Authors:  Carlo Manno; Giovanni F M Strippoli; Loredana Arnesano; Carmen Bonifati; Nicla Campobasso; Loreto Gesualdo; Francesco P Schena
Journal:  Kidney Int       Date:  2004-10       Impact factor: 10.612

7.  Risk management of renal biopsy: 1387 cases over 30 years in a single centre.

Authors:  P Stratta; C Canavese; M Marengo; P Mesiano; L Besso; M Quaglia; D Bergamo; G Monga; G Mazzucco; G Ciccone
Journal:  Eur J Clin Invest       Date:  2007-12       Impact factor: 4.686

8.  Is it necessary to stop antiplatelet agents before a native renal biopsy?

Authors:  Bruce Mackinnon; Emily Fraser; Keith Simpson; Jonathan G Fox; Colin Geddes
Journal:  Nephrol Dial Transplant       Date:  2008-05-25       Impact factor: 5.992

9.  A prospective observational cohort study highlights kidney biopsy findings of lupus nephritis patients in remission who flare following withdrawal of maintenance therapy.

Authors:  Marcelo De Rosa; Francisco Azzato; Jorge E Toblli; Graciela De Rosa; Federico Fuentes; Haikady N Nagaraja; Ryan Nash; Brad H Rovin
Journal:  Kidney Int       Date:  2018-07-23       Impact factor: 10.612

Review 10.  Do we still need renal biopsy in lupus nephritis?

Authors:  Ewa Haładyj; Ricard Cervera
Journal:  Reumatologia       Date:  2016-06-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.